Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakob Ribbing

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|September 24, 2004
Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate ModelJakob Ribbing, E Niclas Jonsson
Computer Methods and Programs in Biomedicine|June 24, 2004
Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programmingLars Lindbom, Jakob Ribbing, E Niclas Jonsson
Journal of Pharmacokinetics and Pharmacodynamics|November 9, 2007
Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studiesJakob Ribbing, Andrew C Hooker, E Niclas Jonsson
Journal of Pharmacokinetics and Pharmacodynamics|May 23, 2007
The lasso--a novel method for predictive covariate model building in nonlinear mixed effects modelsJakob Ribbing, Joakim Nyberg, Ola Caster, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 21, 2025
Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung DiseasesSonja Hartmann, Julie Janssen, Jakob Ribbing, et al.
Journal of Clinical Pharmacology|May 21, 2010
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetesJakob Ribbing, Bengt Hamrén, Maria K Svensson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
Translating Pharmacometrics to a Pharmacoeconomic Model of COPDJulia F Slejko, Richard J Willke, Jakob Ribbing, et al.
British Journal of Clinical Pharmacology|January 24, 2015
A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patientsFei Hua, Jakob Ribbing, Walter Reinisch, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2025
Population Pharmacokinetics and Exposure-Response Model-Based Bayesian Extrapolation of FVC-Based Efficacy Endpoints From Adults to Pediatric Patients Receiving NintedanibSonja Hartmann, Anna Chan Kwong, Jakob Ribbing, et al.
Clinical Pharmacokinetics|March 16, 2013
Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355Paul Matthias Diderichsen, Eugène Cox, Steven W Martin, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Pharmacokinetics and Pharmacodynamics|September 24, 2004
Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate ModelJakob Ribbing, E Niclas Jonsson
Computer Methods and Programs in Biomedicine|June 24, 2004
Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programmingLars Lindbom, Jakob Ribbing, E Niclas Jonsson
Journal of Pharmacokinetics and Pharmacodynamics|November 9, 2007
Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studiesJakob Ribbing, Andrew C Hooker, E Niclas Jonsson
Journal of Pharmacokinetics and Pharmacodynamics|May 23, 2007
The lasso--a novel method for predictive covariate model building in nonlinear mixed effects modelsJakob Ribbing, Joakim Nyberg, Ola Caster, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 21, 2025
Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung DiseasesSonja Hartmann, Julie Janssen, Jakob Ribbing, et al.
Journal of Clinical Pharmacology|May 21, 2010
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetesJakob Ribbing, Bengt Hamrén, Maria K Svensson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
Translating Pharmacometrics to a Pharmacoeconomic Model of COPDJulia F Slejko, Richard J Willke, Jakob Ribbing, et al.
British Journal of Clinical Pharmacology|January 24, 2015
A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patientsFei Hua, Jakob Ribbing, Walter Reinisch, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 9, 2025
Population Pharmacokinetics and Exposure-Response Model-Based Bayesian Extrapolation of FVC-Based Efficacy Endpoints From Adults to Pediatric Patients Receiving NintedanibSonja Hartmann, Anna Chan Kwong, Jakob Ribbing, et al.
Clinical Pharmacokinetics|March 16, 2013
Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355Paul Matthias Diderichsen, Eugène Cox, Steven W Martin, et al.
Pageof 2